Cyclacel Pharmaceuticals to Release Second Quarter 2024 Financial Results
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP), a biopharmaceutical company focused on developing innovative cancer medicines, has announced it will release its second quarter 2024 financial results on Wednesday, August 14, 2024. The company will host a conference call and live webcast at 4:30 p.m. Eastern Daylight Time on the same day to discuss the results.
Investors and interested parties can access the conference call by dialing (800) 225-9448 (US) or (203) 518-9708 (international). The live webcast will be available on the Corporate Presentations page of Cyclacel's website. An audio replay will be accessible for 7 days, while the webcast will be archived for 90 days.
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP), una azienda biofarmaceutica focalizzata sullo sviluppo di medicinali innovativi per il cancro, ha annunciato che pubblicherà i suoi risultati finanziari del secondo trimestre 2024 mercoledì 14 agosto 2024. L'azienda ospiterà una call conferenza e una diretta streaming alle 16:30 ora legale orientale lo stesso giorno per discutere i risultati.
Gli investitori e le parti interessate possono accedere alla call conferenza componendo il numero (800) 225-9448 (US) o (203) 518-9708 (internazionale). La diretta streaming sarà disponibile nella pagina delle Presentazioni Aziendali del sito web di Cyclacel. Una registrazione audio sarà accessibile per 7 giorni, mentre la diretta sarà archiviata per 90 giorni.
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP), una compañía biofarmacéutica enfocada en el desarrollo de medicamentos innovadores contra el cáncer, ha anunciado que dará a conocer sus resultados financieros del segundo trimestre de 2024 el miércoles 14 de agosto de 2024. La compañía llevará a cabo una videoconferencia y transmisión en vivo a las 4:30 p.m. Hora de Verano del Este el mismo día para discutir los resultados.
Los inversores y las partes interesadas pueden acceder a la videoconferencia marcando (800) 225-9448 (EE.UU.) o (203) 518-9708 (internacional). La transmisión en vivo estará disponible en la página de Presentaciones Corporativas del sitio web de Cyclacel. Una grabación de audio estará accesible durante 7 días, mientras que la transmisión se archivará durante 90 días.
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP)는 혁신적인 암 치료제 개발에 집중하는 생명공학 회사로, 2024년 2분기 재무 실적을 2024년 8월 14일 수요일에 발표할 것이라고 발표했습니다. 이 회사는 같은 날 4:30 PM 동부 일광 절약 시간에 컨퍼런스 콜과 라이브 웹캐스트를 개최하여 결과를 논의할 예정입니다.
투자자 및 이해 관계자는 (800) 225-9448 (미국) 또는 (203) 518-9708 (국제)로 전화를 걸어 컨퍼런스 콜에 참여할 수 있습니다. 라이브 웹캐스트는 Cyclacel의 웹사이트의 기업 프레젠테이션 페이지에서 이용 가능합니다. 오디오 재생은 7일 동안 접근할 수 있으며, 웹캐스트는 90일 동안 아카이브됩니다.
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP), une entreprise biopharmaceutique axée sur le développement de médicaments innovants contre le cancer, a annoncé qu'elle publiera ses résultats financiers du deuxième trimestre 2024 le mercredi 14 août 2024. L'entreprise organisera une conférence téléphonique et un webcast en direct le même jour à 16h30, heure avancée de l'Est, pour discuter des résultats.
Les investisseurs et les parties intéressées peuvent accéder à la conférence téléphonique en composant le (800) 225-9448 (États-Unis) ou le (203) 518-9708 (international). Le webcast en direct sera disponible sur la page des présentations d'entreprise du site Web de Cyclacel. Un enregistrement audio sera accessible pendant 7 jours, tandis que le webcast sera archivé pendant 90 jours.
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP), ein biopharmazeutisches Unternehmen, das sich auf die Entwicklung innovativer Krebsmedikamente konzentriert, hat angekündigt, dass es seine Finanzergebnisse für das zweite Quartal 2024 am Mittwoch, den 14. August 2024, veröffentlichen wird. Das Unternehmen wird am selben Tag um 16:30 Uhr Eastern Daylight Time eine Konferenzschaltung und einen Live-Webcast abhalten, um die Ergebnisse zu besprechen.
Investoren und interessierte Parteien können die Konferenzschaltung unter der Telefonnummer (800) 225-9448 (USA) oder (203) 518-9708 (international) erreichen. Der Live-Webcast ist auf der Unternehmenspräsentationsseite von Cyclacels Website verfügbar. Eine Audioaufnahme ist 7 Tage lang abrufbar, während der Webcast 90 Tage lang archiviert wird.
- None.
- None.
BERKELEY HEIGHTS, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce second quarter 2024 financial results on Wednesday, August 14, 2024. The Company will host a conference call and live webcast at 4:30 p.m. Eastern Daylight Time on the same day.
Conference call information:
Call: (800) 225-9448 / international call: (203) 518-9708
Archive: (800) 934-7884 / international archive: (402) 220-6987
Code for live and archived conference call is CYCCQ224. Webcast link
For the live and archived webcast, please visit the Corporate Presentations page on the Cyclacel website at www.cyclacel.com. The webcast will be archived for 90 days and the audio replay for 7 days.
About Cyclacel Pharmaceuticals, Inc.
Cyclacel is a clinical-stage, biopharmaceutical company developing innovative cancer medicines based on cell cycle, transcriptional regulation and mitosis biology. The transcriptional regulation program is evaluating fadraciclib, a CDK2/9 inhibitor, and the anti-mitotic program plogosertib, a PLK1 inhibitor, in patients with both solid tumors and hematological malignancies. Cyclacel's strategy is to build a diversified biopharmaceutical business based on a pipeline of novel drug candidates addressing oncology and hematology indications. For additional information, please visit www.cyclacel.com.
Forward-looking Statements
This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include, among other things, statements related to the intended use of proceeds from the private placement. Factors that may cause actual results to differ materially include market and other conditions, the risk that product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical trials, trials may have difficulty enrolling, Cyclacel may not obtain approval to market its product candidates, the risks associated with reliance on outside financing to meet capital requirements, the risks associated with reliance on collaborative partners for further clinical trials, development and commercialization of product candidates and Cyclacel's ability to regain and maintain compliance with Nasdaq's continued listing requirements. You are urged to consider statements that include the words "may," "will," "would," "could," "should," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal," or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties the Company faces, please refer to our most recent Annual Report on Form 10-K and other periodic and other filings we file with the Securities and Exchange Commission and are available at www.sec.gov. Such forward-looking statements are current only as of the date they are made, and we assume no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
Contacts
| Company: | Paul McBarron, (908) 517-7330, pmcbarron@cyclacel.com |
| Investor Relations: | Grace Kim, IR@cyclacel.com |
© Copyright 2024 Cyclacel Pharmaceuticals, Inc. All Rights Reserved. The Cyclacel logo and Cyclacel® are trademarks of Cyclacel Pharmaceuticals, Inc.
FAQ
When will Cyclacel Pharmaceuticals (CYCC) release its Q2 2024 financial results?
How can investors access Cyclacel's (CYCC) Q2 2024 earnings call?
What time is Cyclacel Pharmaceuticals' (CYCC) Q2 2024 earnings call scheduled?
Where can I find the webcast for Cyclacel's (CYCC) Q2 2024 earnings call?
